MedTrace Logo

Primary Thrombocythaemia 1 Trial

NCT00175838 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1398

Last updated 2017-01-18

No results posted yet for this study

Summary

The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.

Conditions

  • Thrombocythemia
  • Myeloproliferative Disorder

Interventions

DRUG

Hydroxyurea

Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.

DRUG

Aspirin

Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    collaborator OTHER

  • Institute of Cancer Research, United Kingdom

    collaborator OTHER

  • University of Cambridge

    lead OTHER

Principal Investigators

  • Anthony R Green, Prof · Addenbrooke's Hospital and University of Cambridge

  • Claire Harrison, Dr · St Thomas' Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-07-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00175838 on ClinicalTrials.gov